Jazz Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Jazz Pharmaceuticals CEO'su Renee Gala, Oct2023 tarihinde atandı, in görev süresi 2.58 yıldır. in toplam yıllık tazminatı $ 19.15M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.2% maaş ve 94.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.075% ine doğrudan sahiptir ve bu hisseler $ 11.24M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.7 yıl ve 10.1 yıldır.
Anahtar bilgiler
Renee Gala
İcra Kurulu Başkanı
US$19.2m
Toplam tazminat
| CEO maaş yüzdesi | 5.24% |
| CEO görev süresi | 2.6yrs |
| CEO sahipliği | 0.07% |
| Yönetim ortalama görev süresi | 6.7yrs |
| Yönetim Kurulu ortalama görev süresi | 10.1yrs |
Son yönetim güncellemeleri
Recent updates
Analiz Makalesi • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...Analiz Makalesi • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...
Anlatı Güncellemesi • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.
Anlatı Güncellemesi • Apr 13
JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks
Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.Anlatı Güncellemesi • Mar 30
JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks
Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.Anlatı Güncellemesi • Mar 16
JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks
The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.
Anlatı Güncellemesi • Mar 02
JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential
Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.Seeking Alpha • Feb 26
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
Summary Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and 2026 outlook for the oxybate business. Jazz expects Xywav revenues to be flat or up mid-single digits in 2026, despite generic Xyrem headwinds, with the oxybate franchise revenues projected at $1.8-1.9 billion. Strong Modeyso launch and robust Ziihera phase 3 data in first-line GEA set up new growth drivers, with Ziihera's U.S. launch anticipated in 2H 2026. Multiple expansion and valuation re-rating are possible as investors look past widespread availability of Xyrem generics, with Ziihera and other assets supporting (at least) mid-single-digit revenue growth. Read the full article on Seeking Alpha
Yeni Anlatı • Feb 21
Beyond the Patent Cliff: Unlocking the Cash Machine
Jazz Pharmaceuticals (JAZZ), headquartered in Dublin, Ireland, enters 2026 as a highly efficient cash generator that the broader market seems to continually misunderstand. Following a massive 41% earnings beat late last year, the company is proving that it is successfully navigating the transition away from its legacy reliance on the sleep disorder drug Xyrem.Anlatı Güncellemesi • Feb 16
JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership
Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.Anlatı Güncellemesi • Feb 02
JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks
Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.Anlatı Güncellemesi • Jan 19
JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks
Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.Anlatı Güncellemesi • Jan 05
JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist
We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.Anlatı Güncellemesi • Dec 18
JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership
Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.Anlatı Güncellemesi • Dec 04
JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside
Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.Anlatı Güncellemesi • Nov 20
JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology
Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.Analiz Makalesi • Nov 18
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...Anlatı Güncellemesi • Aug 30
Emerging Therapies And Portfolio Expansion Will Shape Future Markets
Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.Analiz Makalesi • Aug 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Last week, you might have seen that Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) released its second-quarter result to the...Analiz Makalesi • Jul 21
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E
With a price-to-earnings (or "P/E") ratio of 14.2x Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) may be sending bullish...Analiz Makalesi • Jul 03
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Dec 23
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Summary Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals. An updated analysis around Jazz Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Summary Jazz Pharmaceuticals is transitioning from Xyrem to Xywav, a low-sodium version with lower cardiac risks but faces competition with more convenient dosing. Strong management with CEO Bruce Cozadd owning $50M+ in shares and a solid balance sheet with Net Debt/EBITDA under 3x. The stock was purchased at under 50% of Base Case NPV, making the downside risk in a Worst Case scenario very modest. Despite some uncertainty, strong financial results and promising pipeline data make the stock deeply undervalued and a continued hold. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$29m |
| Dec 31 2025 | US$19m | US$1m | -US$356m |
| Sep 30 2025 | n/a | n/a | -US$368m |
| Jun 30 2025 | n/a | n/a | -US$405m |
| Mar 31 2025 | n/a | n/a | US$482m |
| Dec 31 2024 | US$7m | US$825k | US$560m |
| Sep 30 2024 | n/a | n/a | US$463m |
| Jun 30 2024 | n/a | n/a | US$395m |
| Mar 31 2024 | n/a | n/a | US$331m |
| Dec 31 2023 | US$5m | US$768k | US$415m |
| Sep 30 2023 | n/a | n/a | US$80m |
| Jun 30 2023 | n/a | n/a | -US$87m |
| Mar 31 2023 | n/a | n/a | -US$156m |
| Dec 31 2022 | US$5m | US$690k | -US$224m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$52m |
| Mar 31 2022 | n/a | n/a | -US$450m |
| Dec 31 2021 | US$5m | US$617k | -US$330m |
| Sep 30 2021 | n/a | n/a | -US$161m |
| Jun 30 2021 | n/a | n/a | US$40m |
| Mar 31 2021 | n/a | n/a | US$518m |
| Dec 31 2020 | US$4m | US$485k | US$239m |
Tazminat ve Piyasa: Renee 'ın toplam tazminatı ($USD 19.15M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 14.80M ).
Tazminat ve Kazançlar: Renee şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.
CEO
Renee Gala (53 yo)
2.6yrs
Görev süresi
US$19,151,558
Tazminat
Ms. Renée D. Galá is an Independent Director of DexCom, Inc. from March 6, 2025. She serves as President at Jazz Pharmaceuticals plc since October 2023 and served as Chief Operating Officer at Jazz Pharmac...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Chairman | 23.3yrs | US$15.32m | 0.54% $ 81.5m | |
| President | 2.6yrs | US$19.15m | 0.075% $ 11.2m | |
| Executive VP & CFO | 2.2yrs | US$7.54m | 0.033% $ 4.9m | |
| Executive VP & Chief Legal Officer | 6.8yrs | US$6.30m | 0.032% $ 4.8m | |
| Executive VP | 7yrs | US$8.61m | 0.064% $ 9.7m | |
| Executive VP & Chief Commercial Officer | 6.2yrs | US$6.08m | 0.027% $ 4.1m | |
| Senior VP & Chief Accounting Officer | 6.8yrs | US$1.45m | Veri yok | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Executive VP & Chief People Officer | 7.5yrs | Veri yok | Veri yok | |
| Senior Vice President of Sleep & CNS Medicine | no data | Veri yok | Veri yok | |
| Senior Vice President of Corporate Strategy | 6.7yrs | Veri yok | Veri yok | |
| Senior Vice President & Chief Transformation Officer | less than a year | Veri yok | Veri yok |
6.7yrs
Ortalama Görev Süresi
53.5yo
Ortalama Yaş
Deneyimli Yönetim: JAZZ 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.7 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Chairman | 23.3yrs | US$15.32m | 0.54% $ 81.5m | |
| President | less than a year | US$19.15m | 0.075% $ 11.2m | |
| Independent Director | 14.3yrs | US$500.56k | 2.04% $ 305.9m | |
| Independent Director | 13yrs | US$518.06k | 0.023% $ 3.4m | |
| Independent Director | 16.8yrs | US$495.56k | 0.028% $ 4.3m | |
| Independent Director | 2.2yrs | US$503.06k | 0.0051% $ 764.6k | |
| Lead Independent Director | 16yrs | US$555.56k | 0.0086% $ 1.3m | |
| Independent Non-Executive Director | 5.4yrs | US$520.56k | 0.012% $ 1.8m | |
| Independent Director | 1.8yrs | US$480.56k | 0.0055% $ 820.1k | |
| Independent Director | 13yrs | US$528.06k | 0.027% $ 4.1m | |
| Independent Non-Executive Director | 5.4yrs | US$490.56k | 0.012% $ 1.8m | |
| Independent Director | 7.3yrs | US$495.56k | 0.021% $ 3.1m |
10.1yrs
Ortalama Görev Süresi
62.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: JAZZ 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.1 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 23:18 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Jazz Pharmaceuticals plc 48 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |